Holen Sie sich die Stockscreener-App
12.00
1.56%
-0.19
Schlusskurs vom Vortag:
$12.19
Offen:
$12.21
24-Stunden-Volumen:
29,218
Relative Volume:
0.40
Marktkapitalisierung:
$846.26M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-1.96%
1M Leistung:
-7.41%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$11.67
$12.53
1-Wochen-Bereich:
$11.67
$12.53
52-Wochen-Spanne:
$7.90
$25.00
Yd Bio Ltd Stock (YDES) Company Profile
Vergleichen Sie YDES mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
YDES
Yd Bio Ltd
|
12.00 | 859.66M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Yd Bio Ltd Aktie (YDES) Neueste Nachrichten
YD Bio Limited Warrants (YDESW) Competitors - Meyka
YD Bio to establish California operations center for diagnostic development By Investing.com - Investing.com Australia
YD Bio to establish California operations center for diagnostic development - Investing.com India
YD Bio (Nasdaq: YDES) plans Calif. ops center for U.S. diagnostics - Stock Titan
Assessing YD Bio (YDES) Valuation After a Sharp One-Month Share Price Rebound - simplywall.st
YD Bio Limited Showcases Its Innovative Diagnostic and Precision Medicine Portfolios at the 9th Healthcare EXPO TAIWAN - Finviz
YD Bio expands cancer detection platform to pancreatic and colorectal cancers - Investing.com Australia
YD Bio expands cancer detection platform to pancreatic and colorectal cancers By Investing.com - Investing.com South Africa
YD Bio Limited Expands OkaiDx™ Testing Portfolio to Pancreatic and Colorectal Cancer Detection Across the U.S. and Provides Clinical Research Update on Pancreatic Cancer Early Detection - Yahoo Finance
YD Bio (Nasdaq: YDES) widens OkaiDx to 44 states, shows 93.8% early pancreatic sensitivity - Stock Titan
YD Bio Limited (YDESW) stock historical prices and data - Yahoo Finance UK
Micron, Endeavour Silver, First Majestic Silver, Applied Digital And Other Big Stocks Moving Higher On Friday - Benzinga
Urban Outfitters, Arrowhead Pharmaceuticals, Petco Health and Wellness And Other Big Stocks Moving Higher On WednesdayArrowhead Pharma (NASDAQ:ARWR), Duolingo (NASDAQ:DUOL) - Benzinga
Tesla, Micron among market cap stock movers on Monday By Investing.com - Investing.com Australia
YD Bio stock rises after FDA clearance for eye care products - Investing.com Nigeria
YD Bio Stock Rises On Entry Into US Eye Care Segment - MSN
YD Bio receives FDA clearance for contact lenses and artificial tears - Investing.com India
Kyivstar Launches Starlink Direct to Cell Satellite Connectivity in Ukraine - The Manila Times
OMG Announces 28th Edition of Journal of Innovation - The Manila Times
Connect Biopharma to Present at the 8th Annual Evercore Healthcare Conference - The Manila Times
YD Bio Limited Announces U.S. Ophthalmology Market Entry, Advances Across Diagnostics and LSC Exosome Therapeutics - Yahoo Finance
YD Bio Limited (YDESW) Stock Historical Prices & Data - Yahoo! Finance Canada
YD Bio Limited (YDESW) company profile and facts - Yahoo Finance UK
[424B3] YD Bio Ltd Prospectus Filed Pursuant to Rule 424(b)(3) - Stock Titan
[6-K] YD Bio Ltd Current Report (Foreign Issuer) | YDES SEC FilingForm 6-K - Stock Titan
YD Bio Limited Announces Board and Committee Changes - MarketScreener
S&P 500, Nasdaq and Dow Jones see big rise as heavyweight tech stocks witness rebound: Check top gainers a - The Economic Times
YD Bio (NASDAQ: YDES) opens U.S. OkaiDx RUO access via CLIA/CAP lab; 95.1% accuracy - Stock Titan
YD Bio and EG BioMed Expand U.S. Access to OkaiDx™, a cfDNA‑Methylation Blood Test for Post‑Treatment Breast Cancer Monitoring - Yahoo Finance
YD Bio plunges 52% after InvestingPro’s overvaluation warning By Investing.com - Investing.com Australia
YD Bio Ltd. Rings Nasdaq Opening Bell to Celebrate Listing under Ticker YDES - The Manila Times
GYMD Showcases Industrial AI and Digitalization Strength at Tech Week Singapore 2025 - The Manila Times
20‑Year Exclusive Licenses — YD Bio Lists as YDES on Nasdaq to Scale cfDNA cancer tests and eye therapies - Stock Titan
YD Bio Limited (YDESW) Stock Price, News, Quote & History - Yahoo
YD Bio Ltd (YDES) latest press releases and corporate news - Yahoo
YD Bio Ltd (YDES) cash flow - Yahoo
YD Bio Ltd (YDES) Valuation Measures & Financial Statistics - Yahoo
Metals & Mining Virtual Investor Conference: Presentations Now Available for Online Viewing - The Manila Times
YD Bio Business Partner EG Biomed Achieves CAP Accreditation, Advancing U.S. Clinical Testing Capabilities - Yahoo Finance
CAP Accreditation Secured: YD Bio partner EG BioMed's CLIA lab in Bothell bolsters U.S. cancer testing capabilities - Stock Titan
YD Bio Limited Reports Unaudited Half Year 2025 Financial Results - BioSpace
MARTEN TRANSPORT CLOSES ON THE SALE OF ASSETS RELATED TO INTERMODAL BUSINESS - The Manila Times
Hub Group Closes on the Acquisition of Marten Transport Intermodal - The Manila Times
Three Small-Caps Took Off On News And Fresh Deals - Finimize
YD Bio announces COO resignation and updates on public warrant registration By Investing.com - Investing.com Nigeria
YD Bio announces COO resignation and updates on public warrant registration - Investing.com
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Concentrix Posts Downbeat Earnings, Joins Legacy Education, Kingsoft Cloud And Other Big Stocks Moving Lower In Friday's Pre-Market SessionApellis Pharmaceuticals (NASDAQ:APLS), Concentrix (NASDAQ:CNXC) - Benzinga
Freeport-McMoRan, Harmony Biosciences, Cohu, And Other Big Stocks Moving Lower On Wednesday - Benzinga
Finanzdaten der Yd Bio Ltd-Aktie (YDES)
Es liegen keine Finanzdaten für Yd Bio Ltd (YDES) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):